Announcements Trials

Browse Landscape

Phase

Status

Completed 31 Active not recruiting 23 Recruiting 22 Terminated 7 Approved for marketing 2 Withdrawn 1

Sponsor Class

OTHER 9 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Paclitaxel 31 Cyclophosphamide 30 Cisplatin 29 Bevacizumab 28 Carboplatin 27 Fluorouracil 24 pembrolizumab 21 Nivolumab 21 Leucovorin 20 Rituximab 19 avelumab 18 Gemcitabine 18 Docetaxel 18 Dexamethasone 18 Capecitabine 17 ALT-803 15 130-nm albumin-bound paclitaxel 14 Oxaliplatin 12 Cetuximab 12 fludarabine 11 Ipilimumab 11 venetoclax 10 atezolizumab 10 Radiosurgery 10 Radiotherapy 9 Pemetrexed 9 Omacor 9 Lenalidomide 9 Bendamustine Hydrochloride 9 yeast-CEA vaccine 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × INDUSTRY × abemaciclib × Clear all

NCT03988114 2019-09-06

proMONARCH

Eli Lilly and Company

Phase 4 Withdrawn

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡